Nanoscope Therapeutics announced that clinical data from its phase 2b/3 RESTORE trial and the long-term REMAIN follow-up study will be presented at the FLORetina-ICOOR 2025 Congress, taking place December 4–7 at the Fortezza da Basso in Florence, Italy.

The upcoming presentations by Jordi Monés, MD, PhD, and Allen C. Ho, MD, will highlight the sustained 3-year efficacy and safety of Nanoscope’s proprietary optogenetic therapy, MCO-010, delivered via a single intravitreal injection to patients with advanced retinitis pigmentosa (RP). Findings from the RESTORE and REMAIN studies continue to demonstrate durable, meaningful improvements in visual function for individuals with severe vision loss.

“As demonstrated in these studies, achieving consistent 3-line visual improvement for more than 3 years from a single dose of MCO-010 is a remarkable outcome for patients with severe vision loss due to retinitis pigmentosa,” said Dr. Monés, Director of Institut de la Màcula and the Barcelona Macula Foundation. “I am excited to share these results, as well as the strong safety profile of MCO-010, at the FLORetina-ICCOR Annual Congress, which will include some of the world's leading experts in treating vitreoretinal diseases.”

Presentation Details

1. REMAIN: 3-year Long-term Follow-up from RESTORE Evaluating Efficacy and Safety of MCO-010 Optogenetic Therapy in Advanced Retinitis Pigmentosa

  • Presenter: Jordi Monés, MD, PhD – Director, Institut de la Màcula & Barcelona Macula Foundation (Spain)

  • Date/Time: Friday, December 5 | 9:18 CET

  • Session: Highlighted Free Papers 2

  • Location: Del Carmine Room

2. Longitudinal Efficacy and Safety of MCO-010 Optogenetic Therapy for Vision Restoration in Patients with Severe Vision Loss Due to Retinitis Pigmentosa

  • Presenter: Allen C. Ho, MD – Director of Retina Research, Wills Eye Hospital; Chief Medical Advisor, Nanoscope Therapeutics

  • Date/Time: Saturday, December 6 | 11:18 CET

  • Session: Retina Futura – Spotlight on Emerging Therapies for Inherited Retinal Diseases

  • Location: Sante Croce Room

MCO-010 has received Fast Track and Orphan Drug designations from the FDA, and a rolling Biologics License Application (BLA) for treatment of retinitis pigmentosa is currently underway. In Europe, the European Medicines Agency (EMA) has granted MCO-010 five Orphan designations spanning a broad array of retinal degenerative conditions characterized by photoreceptor loss.